GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Forward PE Ratio

QTTB (Q32 Bio) Forward PE Ratio : 0.00 (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Forward PE Ratio?

Q32 Bio's Forward PE Ratio for today is 0.00.

Q32 Bio's PE Ratio without NRI for today is 0.00.

Q32 Bio's PE Ratio (TTM) for today is 0.00.


Q32 Bio Forward PE Ratio Historical Data

The historical data trend for Q32 Bio's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Forward PE Ratio Chart

Q32 Bio Annual Data
Trend
Forward PE Ratio

Q32 Bio Quarterly Data
Forward PE Ratio

Competitive Comparison of Q32 Bio's Forward PE Ratio

For the Biotechnology subindustry, Q32 Bio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q32 Bio's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Q32 Bio's Forward PE Ratio falls into.



Q32 Bio Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Q32 Bio  (NAS:QTTB) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Q32 Bio Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Q32 Bio Business Description

Comparable Companies
Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.